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Abstract 
 
Background: Trichomoniasis vaginalis is now an important worldwide health problem. Metronidazole has so far 
been used in treatment, but the metronidazole-resistant strains and unpleasant adverse effects have been de-
veloped. Myrrh is one of the oldest known medicinal plants used by the ancient Egyptians for medical purposes 
and for mummification. Commiphora molmol (Myrrh) proved safe for male reproductive organ which is the main 
habitat of T. vaginalis and this study aims to evaluate the efficacy of the herbal against T. vaginalis in females. 
 
Methods: In the present study, 33 metronidazole-resistant T. vaginalis females were treated with a combined 
course of metronidazole and tinidazole. Those still resistant to the combined treatment were given C. molmol. 
Also, natural plant extract purified from pomegranate (Punica granatum, Roman) was in-vitro investigated for its 
efficacy against T. vaginalis on Diamond media. 
 
Results: The anti-T. vaginalis activity of both P. granatum (in-vitro) and C. molmol (in-vivo) extracts gave promis-
ing results. 
 
Conclusion: The anti-T. vaginalis activity of P. granatum and C. molmol showed promising results indicating to 
sources of new anti-Ttrichomonas agents. 
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Introduction 
 
Although Trichomonas vaginalis was first described 
by Donne' in 1836, research on this organism did not 
begin until the 20
th century. The research has been a 
progression of phases throughout the last 60 years 
and has gone from developing axenic culture and de-
fining nutritional requirements to finding an effective 
treatment.
1 It was considered either a harmless vagi-
nal colonizer or simply a minor nuisance.
2 Trichomo-
niasis was accounted to about half of all the curable 
sexually transmitted diseases worldwide.
3 The inci-
dence of this sexually transmitted parasite has 
reached the epidemic levels in many countries.
4 Also, 
T. vaginalis survived in swimming pool, where hu-
man may acquire infection.
5 In USA, annual inci-
dence of T. vaginalis reached 5 millions.
6 The general 
annual adult infection was 180-200 millions and be-
ing higher than that of gonorrhea, syphilis, and Chla-
mydia infections all together.
7 In many Arab coun-
tries, trichomoniasis was reported including Jordan,
8 
Iraq,
9 Egypt,
10 Saudi Arabia,
11 Libya,
12 and Tunisia.
13  
The wide diversion in subtypes of T. vaginalis iso-
lates caused different clinical symptoms with diversi-
ty of innate immune responses.
14 The infection was 
always associated with other sexually-transmitted 
diseases (STDs) and a sensitive marker for high risk 
sexual behaviour.
15 T. vaginalis in males caused non-
gonococcal urethritis,
16 but with serious complica-
tions.
17  Also,  T. vaginalis adherence was shown to 
mediate different gene expressions in human epitheli-
al cells.
18 The premature rupture of membranes, low-
birth weight, preterm labor,
19 female infertility,
20 and 
postpartum infection, even in asymptomatic women 
were associated with trichomoniasis.
21 T. vaginalis is 
a factor in genesis and cause of cervical neoplasia,
22 
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and progression of cervical carcinoma,
23 also phago-
cytes sperm cells.
24 Unlike other STDs, T. vaginalis 
rate was more prevalent among women of all ages,
25 
and half of them were asymptomatic
26 since tricho-
moniasis was a curable infection by a single dose 
metronidazole,
27 successful control of STDs was aid-
ed by sensitive, simple and rapid test(s). No doubt, 
treating patients lowered the overall disease preva-
lence and morbidity.
28 Metronidazole has so far been 
the most widely used drug for treating T. vaginalis,
29 
but, metronidazole can lead to drug resistance and 
potential risks of mutagenesis and carcinogenicity.
30 
In addition, its side effects such as headache, dry 
mouth, glossitis, and urticaria caused by lenity treat-
ment or high doses have been described.
31 But, at 
least 5% of clinical trichomoniasis is caused by 
strains resistant to commonly used drugs.
32 Also, 
Hussien  et al.
32 reported the presence of different 
strains of T. vaginalis. The lack of approved alterna-
tive therapies for T. vaginalis treatment means that 
higher and sometimes toxic doses of metronidazole 
were used.
33 Tinidazole (Fasigyn), a second-
nitronidazole generation has shown to be an effective 
therapy in metronidazole-resistant T. vaginalis, with 
several advantages over metronidazole including 
greater in vitro potency against both sensitive and 
resistant strains of T. vaginalis, a more prolonged du-
ration and improved patient tolerability.
34 Cross-
resistance among mitronidazole doses occurred, and 
thus metronidazole resistant strain was treated with 
tinidazole but rapid development of tinidazole-
resistant T. vaginalis due to the similarities of meta-
bolic pathway of both.
4  
According to world health organization (WHO), 
more than 80% of the world's population relies on 
traditional medicine for their primary healthcare 
needs. Use of herbal medicines represents a long his-
tory of human interactions with the environment. 
Plants used for traditional medicine contain a wide 
range of substances that can be used to treat chronic 
as well as infectious diseases.
35 The medical value of 
plants lies in some chemical substances that produce 
a definite physiological action on the human body. 
The most important of these bioactive compounds of 
plants are alkaloids, flavanoids, tannins, and phenolic 
compounds.
36 
Natural products are not only the basis for tradi-
tional or ethnic medicine, but also screening natural 
plant products provided highly successful new regi-
mens for human welfare.
37 Many new natural product 
groups have revealed anti-parasitic properties of sur-
prising efficacy and selectivity.
38 In the present study, 
Mirazid was given to metronidazole and tinidazole 
resistant T. vaginalis infected women. Also, the effi-
cacy of Punica granatum extract against cultured T. 
vaginalis was evaluated. 
 
 
Materials and Methods 
 
The institutional review board of hospital approved 
this study. The study was registered at the Ministry of 
Scientific Research Academy of Scientific Research 
and Technology (292473). 
We informed women to allow for an attrition rate 
(i.e. women who discontinue participation in the study 
entirely, including failure to complete all follow-up). 
Thus, 33 women were available to be studied.  
The patients were recruited from hospitals of Cai-
ro Curative Organization of Egypt. Potentially eligi-
ble patients were identified through hospitals regis-
tries for a 3-years retrospective inclusion, and through 
treating physicians, for the 2 years prospective inclu-
sion (Patient who met the case definition of metroni-
dazole resistant vaginal trichomoniasis were select-
ed). A letter was sent for them while had been signed 
by their physician informing them of the study proto-
col and, if initially interested, asking them to com-
plete a brief questionnaire to screen for trichomonia-
sis symptoms. Women who were assigned into con-
trol group were given the choice of undergoing the 
study program. 
Metronidazole- resistant trichomoniasis was de-
fined clinically as failure to respond to conventional 
therapy with oral metronidazole, 500 mg for 7 days 
(Total dose, 7 g). Patients in whom treatment failed 
and for whom re-infection from a sexual partner was 
a possibility were excluded from the study. "Failure 
to respond" was defined as persistence or recurrence 
(with 28 days) of symptoms and signs of vaginitis 
together with the following confirmatory laboratory 
feature of vaginal trichomoniasis: high vaginal pH, 
increased numbers of polymorphonclear leukocytes, 
and a visualization of motile trichomonads using mi-
croscopy. In vitro Trichomonas cultures of individual 
specimens were performed using Dimoned's medium 
Modified (Remel), and they were examined at 24 hr 
and 48 h for the presence of motile trichomonads.   
Two vaginal swabs were obtained from the 
childbearing period trichomoniasis infected women 
by sterile vaginal swab. The first swab was obtained 
from the lateral wall of vagina and was used to make Sherbiny et al. 
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a wet mount preparation on a glass slide with a drop 
of normal saline and looking for motile trichomon-
ads.
39 The second swab was obtained from the poste-
rior fornix of the vagina and inoculated immediately 
after collection in Diamond media at 32
oC and exam-
ined for motile trichomonades at 24, 48, and 96 hr of 
incubation.
40 The efficacy of metronidazole and tin-
dazole was evaluated in 33 patients. Both drugs were 
given orally in a single dose of 2 g for a minimum of 
3 days or extended as indicated. A combination of 
vaginal metronidazole and oral tinidazole was tried. 
The effectiveness of an oleo-resin extract derived 
from Myrrh, Commiphora molmol (Mirazid) was giv-
en to the metronidazole and tinidazole resistant fe-
males as two capsules (600 mg) for six to eight suc-
cessive days on an empty stomach two hours before 
breakfast. All  patients were seen immediately after 
treatment completion and again 4 to 6 week later. Pa-
tients were considered cured if all symptoms and 
signs of vaginal trichomoniasis resolved with therapy 
and the patients had negative results of microscopy at 
least 4 weeks after completion of therapy. In the ma-
jority of patients, a follow- up culture was performed. 
Patients were also instructed to notify investigators if 
symptoms returned after the final follow-up visit.   
Follow up was done both clinically and parasitologi-
cally by the examination of vaginal discharge as wet 
mount smear and culture on Diamond media. 
Punica granatum fruits were selected from tree 
that was neither treated with any insecticide nor with 
plant fertilizer. The fruits were carefully washed with 
sterile distilled water. The peels of pomegranate fruits 
were manually removed, sun dried and powdered. 
Powder was extracted with a Soxhlet extractor using 
methanol for 24 hr.
41 Extract was filtered through a 
Whatman filter, No. 41 filter paper, for removal of 
peel particles (Solvent was removed under gentle 
pressure in rotary evaporator till dryness, and residue 
was stored at 4
oC).
42 Extract was tested at different con-
centrations, diluted with sterile normal saline against 
cultured T. vaginalis. Control culture lacked extract. All 
culture-media were incubated at 37
oC and examined for 
living T. vaginalis (Figure 1 and 2). The results are ex-
pressed as means and values were evaluated by the Chi 
Square test and p<0.5 was considered significant. 
 
 
Results 
 
Review of medical records revealed 33 cases of met-
ronidazole- resistant trichomoniasis seen during a   
 
 
Fig. 1: Normal T. vaginalis stained by ZN 
 
 
Fig. 2: ZN stained smear showing lethal effect of P. 
granatum on T. Vaginalis 
 
 
3 years period (2005-2008). The mean age of the fe-
male patient was 37.2 years (range= 25-58 years). 
Duration of vulvovaginal symptoms was from 4 
months to 5 years. Seventy five percent of referred 
women had previously diagnosed resistant trichomo-
niasis, and 25% of the women were referred because 
of refractory vaginitis of unknown aetiology. Before 
referral, all patients had received and did not respond 
to multiple courses of oral metronidazole.   
Fifty percent of patients (9/18) given oral 
tinidazole were cured and 73% of patients (11/15) 
given a combination of oral metronidazole and vagi-
nal tinidazole were treated (Table 1). Besides, This 
figure for patients who did not respond to combina-
tion of metronidazole and tinidazole oral or vaginal 
and were cured by Mirazid was 84.6% (11/13). In 
vitro susceptibility of isolates of T. vaginalis to  P. 
granatum extract was determined. At pH=4.65, P. 
granatum showed a therapeutic effect against T. 
vaginalis, the organism was dead immediately in the C. molmol in vaginal trichomoniasis 
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tube containing 50 mg and100 mg of the extract, and 
within 0.5 hour in the tube with 20 mg extract. At 
pH=6.00, however, P. granatum extract had no effect 
against the organism.  
 
 
Discussion 
 
There is a need for studies into other chemicals and/or 
medicinal plants or herbs for alternative regimens 
against T. vaginalis to be inexpensive, effective, safe 
to use and with short course of treatment. Globally, 
herbal remedies have been studied under rigorous 
controls and was technologically approved by authors 
in many countries. 
Factors that predispose women to vulvovaginitis 
candidiasis and trichomoniasis are pregnancy, diabe-
tes, HIV infection, higher dosage of oral antibiotics or 
corticosteroid use, immunosuppression, more patho-
genic normal flora, and history of recurrent infection. 
Other factors that may increase the incidence include 
the use of perfumed feminine hygienic sprays, tropi-
cal antimicrobial agents, and tight poorly ventilated 
clothing and under wear.
43  
Successful determination of biologically active 
compounds from plant material is largely dependant 
on the type of solvent used in the extraction proce-
dure, properties of a good solvent in plant extraction 
that induces ease of evaporation at low heat, promo-
tion of rapid physiologic absorption of the extract, a 
preservative action and inability to cause the extract 
to complex or dissociate.
44 The choice will also de-
pend on targeted compounds. The most commonly 
used solvents for investigation of microbial activity in 
plants are methanol, ethanol, and water.
45 In this 
study methanol extract was used.  
In the present study, P. granatum extract on T. 
vaginalis in Diamond media showed 100% efficacy 
in dilution up to 10%. On the other hand, extracts in 
the concentrations of 5%, 1% & 0.5% killed 40%, 
25% & 10% of T. vaginalis respectively. 
Metronidazole has a worldwide use within the last 
2 years of its introduction, but the lack of surveillance 
data of vaginal trichomoniasis and clinical and mi-
crobiological response to treatment, incidence of met-
ronidazole resistance has spared.  Lossick and Kent
46 
found that the high level resistance to metronidazole 
occurred in one out of 2000-3000 cases of vaginal 
trichomoniasis cases. Saurina et al.
47 studied the 
prevalence of in vitro metronidazole resistance among 
outpatients attended urban clinic, found that 3/118 
(2.5%) of T. vaginalis isolates from 107 patients ex-
hibited aerobic low level resistance. The development 
of drug resistance in human against commonly used 
treatments has necessitated a search for new anti-
agent substances from other sources including 
plants.
48 Myrrh is an oleo-gum resin obtained from 
the stem of the herbal tree Commiphora molmol. It 
contains a resin (Myrrhin) which is a volatile oil 
(Myrrh), gum and a bitter principle.
49 Myrrh was used 
by Sumerians and Greeks to treat worms, stomach 
pain, flatulence particularly in children,
50 anti-
inflammatory, anti-ulcer, anti-mutagenic, anti-
cytotoxic, anti-carcinogenic,
51 and anti-diabetic prop-
erties.
52 Also, C. myrrha and various other species of 
Commiphora are recognized to possess significant 
antiseptic, anesthetic, and anti-tumor properties.
53 Its 
safety and effectiveness was proved in the treatment 
of human schistosmoiasis,
54-56 fascioliasis of human,
57 
and animals,
58 moniziasis,
59 strongyloidiasis,
60 heter-
ophyiasis,
61 and both species of hymenolepiasis.
62 
Also, myrrh has larvicidal action against larvae of 
both Culex pipiens and Aedes caspius,
54 molluscicidal 
action against  Biomphalaria alexandrina, Bulinus 
truncatus and Lymnaea cailliaudi,
63 Bithynia connol-
lyi, the snail vector of the trematod parasite Opisthor-
chis sp.,
64 and  Lymnaea natalensis.
65  C. molmol 
proved safe for male reproductive organs which is the 
main habitat of T. vaginalis.
66 Omar et al.
67 tested the 
safety of mirazid on adult male albino rats by assess-
ment of serum levels of ALT, AST and bilirubin and 
histopathology of liver. They found a non-significant 
increase in these enzymes and bilirubin levels. Auffray
68 
in France stated that essential oil of C. myrrha ha the 
best protection against squalene per oxidation, and that 
Table 1: Trichomoniasis cases treated by metronidazole & tinidazole.
Drug used   Total Cure Not                    %Cure
Tinidazole 18 9 9  50
Oral metronidazole +  vaginal tinidazole   15  11  4  73 
Total  33 20 13  60.6 
 Sherbiny et al. 
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sun care cosmetics should make use not only of free 
radical scavengers but also of singlet oxygen quenchers.  
The Pomegranate fruit has been used for centuries 
in ancient cultures for its medicinal purposes. It is 
widely consumed fresh and in beverage forms as 
juice and wine.
69 Properties attributed to its high con-
tent of polyphenols, including ellagic acid in its free 
and bound forms, and other flavouroids.
70 In the last 
two decades, many authors dealt with P. granatum 
(Pomegranate) as a medicinal plant.
71 It is a shrub or 
small tree which several parts have been used by old 
Indian physicians. Nowadays, parts of pomegranate 
are used as an astringent, anti-microbial hemostatic, 
anti-diabetes, anti-helminthes,
72 anti-prostate cancer,
73 
improved anti-oxidant function in elderly subjects,
74 
anti-fungal peptide,
75 and anti-Candida,
76 mouth-anti-
T. Gingivalis,
77 as heart-healthy juice,
78 and preven-
tion of the cardiovascular diseases.
79 Dried per carp 
was decocted with other herbs and used to treat colic, 
dysentery, leucorrhoea,
80 and as larvicide against my-
iasis producing larvae of Lucilia sericata.
81 Also, the 
rind of fruit and flower, combined with aromatics, 
such as cloves, cinnamon, coriander, pepper etc as 
bowel astringent in the diarrhea.
82 It was used exter-
nally in treatment of the vaginal discharge, mouth 
sores, and throat infections.
83 Methanol extracts of P. 
granatum fruit exhibited a higher degree of antimi-
crobial activity.
84 The fruit was successfully used to 
treat dysentery, diarrhea and gastralgia.
85 Voraavu 
Thikunchai et al.
86 reported that P. granatum contains 
25% tannins which made it an effective astringent. In 
old medicine, the pomegranate as a pharmacy unto 
itself was used as an anti-parasitic agent, a blood ton-
ic and to heal apathies and ulcers.
87 
This study shows statistically significant effects on 
resistant T. vaginalis strains. These proposed benefits, 
however, are in assays that are as yet invalidated, and 
further research is needed to prove the validity of these 
tests. In conclusion, the results in the present study 
support the two safe plant extracts (Commiphora 
molmol and Punica granatum) proved to be valuable 
agents in treating of T. vaginalis infection, and will 
form the basis for further investigation in the potential 
discovery of new natural bioactive compounds. 
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